{
    "clinical_study": {
        "@rank": "124504", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 (Low Dose)", 
                "arm_group_type": "Active Comparator", 
                "description": "The group will receive the lowest dose of the vaccine"
            }, 
            {
                "arm_group_label": "Cohort 2 (Mid Dose)", 
                "arm_group_type": "Active Comparator", 
                "description": "The Group will receive the middle dose of the vaccine"
            }, 
            {
                "arm_group_label": "Cohort 3 (High Dose)", 
                "arm_group_type": "Active Comparator", 
                "description": "The Group will receive the highest dose of vaccine to be tested"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase I, open-label, sequential-cohort, ascending multiple-dose study to evaluate the safety\n      and tolerability of escalating doses of PDS0101 in female subjects with high-risk HPV\n      infection and biopsy-proven CIN1. The study will include 3 cohorts of 3 to 6 subjects each\n      based on a modified \"3 + 3\" dose-escalation study design.  The study will be initiated with\n      Cohort 1 and progress through Cohort 3, with each subsequent cohort receiving a higher dose\n      of PDS0101.  Successive cohorts will receive a constant dose of HPV-16 E6 and E7 peptides.\n      All subjects will receive 3 vaccinations SC given approximately 21 days apart.  Dosing and\n      dose escalation will be based on safety evaluation for determination of potential\n      dose-limiting toxicity (DLT)."
        }, 
        "brief_title": "An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101", 
        "condition": "Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 in Female Subjects With High-risk HPV Infection and Biopsy-proven CIN1.", 
        "condition_browse": {
            "mesh_term": "Cervical Intraepithelial Neoplasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent prior to initiation of any study-related procedures;\n\n          2. Nonlactating female between the ages of 21 to 65 years, inclusive;\n\n          3. Non-childbearing potential (defined as surgically sterile or at least 2 years\n             postmenopausal) or practicing effective contraception (defined as 2 concurrent\n             methods of contraception, 1 of which is a barrier method) and agrees to continue\n             using effective contraception throughout the duration of the study;\n\n          4. Not pregnant based on a negative result on a serum human chorionic gonadotropin (HCG)\n             test at screening Visit 1 and a negative urine pregnancy test prevaccination at Visit\n             2 (and at subsequent vaccination visits);\n\n          5. Pap test documenting atypical squamous cells of undetermined significance\n             (ASCUS)/HPV+, atypical squamous cells high grade (ASC-H), low-grade squamous\n             intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL)\n             within 4 months prior to screening Visit 1;\n\n          6. History of pathologically confirmed CIN1 by colposcopically-directed punch biopsy,\n             within 12 weeks prior to administration of first study vaccination (CIN 2/3 subjects\n             will not be eligible);\n\n          7. For the diagnosis of CIN1, has a documented satisfactory colposcopy, ie, the entire\n             lesion as well as the entire squamocolumnar junction is visualizible by colposcopy;\n\n          8. Confirmed high-risk HPV infection by a commercially available high-risk DNA assay\n             (eg, Hybrid Capture II [Qiagen]);\n\n          9. Good health with adequate hematologic, renal, hepatic, and cardiac function, as\n             determined by the Investigator, based upon medical history, physical examination, and\n             laboratory test results at the screening visit (Visit 1):\n\n               -  Bone marrow function: absolute neutrophil count \u22651,500/\u00b5L, and platelets \u2265\n                  100,000/ \u00b5L;\n\n               -  Renal function:  creatinine \u2264 1.5 x institutional upper limit of normal (ULN);\n\n               -  Hepatic function: total bilirubin \u2264 1.5 x ULN (Common Terminology Criteria for\n                  AEs [CTCAE] v4.0 grade 1) except patients with Gilbert's disease (up to 5.0\n                  mg/dL).  Aspartate aminotransferase (AST) and alkaline phosphatase \u2264 2.5 x ULN.\n\n               -  Normal Cardiac function:  as assessed by history and physical exam.\n\n        Exclusion Criteria:\n\n          1. Atypical endometrial or glandular cells or evidence of invasive cervical carcinoma on\n             cervical biopsy;\n\n          2. Previous history of cancer, other than adequately treated basal cell or Stage 1\n             squamous cell carcinoma of the skin;\n\n          3. Current recognized immunodeficiency disease, including infection with HIV, cellular\n             immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia, or hereditary or\n             congenital immunodeficiencies.\n\n          4. Received immunotherapy (eg, IFNs, tumor necrosis factor, interleukins, or biological\n             response modifiers [granulocyte-macrophage colony-stimulating factor, granulocyte\n             colony-stimulating factor, macrophage colony-stimulating factor]) within 30 days\n             prior to administration of the first study vaccination;\n\n          5. Serious, concomitant disorder, including active systemic infection requiring\n             treatment, in the opinion of the investigator;\n\n          6. Currently receiving or has received treatment with systemic steroids in the following\n             dosages within 30 days prior to administration of the first study vaccination.\n\n               -  Chronic or long-term corticosteroids: \u22650.5 mg/kg/day of oral prednisolone or\n                  equivalent\n\n               -  Sporadic corticosteroids: \u22651 mg/kg/day of oral prednisolone or equivalent for 2\n                  or more short courses of > 3 days\n\n               -  Note:  Current or recent use of intra-articular, topical or inhaled\n                  glucocorticoid therapy is acceptable;\n\n          7. Other condition or prior therapy that, in the opinion of the Investigator,\n             compromises the subject's welfare or may confound study results;\n\n          8. Participation in another investigational study concurrently or use of another\n             investigational drug within 6 months prior to administration of  the first study\n             vaccination;\n\n          9. Previously enrolled in this study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065973", 
            "org_study_id": "U10-02-11-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1 (Low Dose)", 
                "Cohort 2 (Mid Dose)", 
                "Cohort 3 (High Dose)"
            ], 
            "intervention_name": "R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Port Jefferson", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11777"
                }, 
                "name": "Suffolk Obstetrics & Gynecology"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 in Subjects With Cervical Intraepithelial Neoplasia (CIN) and High-risk Human Papillomavirus (HPV) Infection", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation or determination of adverse events following vaccination", 
            "safety_issue": "Yes", 
            "time_frame": "Days 1-133"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065973"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "PDS Biotechnology Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PDS Biotechnology Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}